NCT05488860 is a NA clinical trial of Triamcinolone acetonide(scar)/5-ALA(others) in Skin Diseases, sponsored by Xiangya Hospital of Central South University.

Who is sponsoring NCT05488860?

NCT05488860 is sponsored by Xiangya Hospital of Central South University.

What drugs are being tested in NCT05488860?

Interventions in NCT05488860: Triamcinolone acetonide(scar)/5-ALA(others), Piezoelectric drived microneedling, 5-ALA (a photosensitizer for photodynamic therapy)..

What condition does NCT05488860 study?

NCT05488860 studies Skin Diseases, Hypertrophic Scar, Keloid, Plantar Wart, Warts, Skin Tumor.

Is NCT05488860 still recruiting?

NCT05488860 is currently status unknown. Last updated 5 August 2022.

Last reviewed 2022-08-05 · How we verify

NCT05488860

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Piezoelectric Drived Microneedling in Treating Refractory Skin Diseases

Status unknown NA Last updated 5 August 2022

What this trial tests

NA trial testing Triamcinolone acetonide(scar)/5-ALA(others) in Skin Diseases in 20 participants. Status unknown.

Timeline

30 July 2022

Primary endpoint
30 June 2024

31 July 2024

Quick facts

Lead sponsor	Xiangya Hospital of Central South University
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	20
Start date	30 July 2022
Primary completion	30 June 2024
Estimated completion	31 July 2024
Sites	1 location across China

Drugs / interventions tested

Triamcinolone acetonide(scar)/5-ALA(others) — full drug profile →
Piezoelectric drived microneedling
5-ALA (a photosensitizer for photodynamic therapy). — full drug profile →

Conditions studied

Skin Diseases — all drugs for Skin Diseases →
Hypertrophic Scar — all drugs for Hypertrophic Scar →
Keloid — all drugs for Keloid →
Plantar Wart — all drugs for Plantar Wart →

Sponsor

Xiangya Hospital of Central South University

Who can join

16 and older, any sex, with Skin Diseases or Hypertrophic Scar. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Piezoelectric drived microneedling treats refractory skin disorders using hollow microneedles assisted by ultrasound. Mechanically, the injection of medicine by hollow microneedling could makes the distribution of medicine more evenly. And the addition of ultrasound technique improves the effectiveness of microneedling. Investigators plan to conduct a pilot study to investigate the efficacy of using piezoelectric drived microneedles in treating refractory skin diseases.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Trial watch: an update of clinical advances in photodynamic therapy and its immunoadjuvant properties for cancer treatment.
Penetra M, Arnaut LG, Gomes-da-Silva LC. · · 2023 · cited 36× · PMID 37346450 · DOI 10.1080/2162402x.2023.2226535
A piezoelectric-driven microneedle platform for skin disease therapy.
Chen Z, Liu X, Jiang Z, Wu H, et al · · 2024 · cited 13× · PMID 38680817 · DOI 10.1016/j.xinn.2024.100621
Current State of Clinical Trials for Keloid Management: An Analysis of Trials Registered on ClinicalTrials.gov.
Park S, Li D, Guo L, Xu X. · · 2026 · PMID 42077711 · DOI 10.7759/cureus.106243

Verify or expand the search:

Other recruiting trials for Skin Diseases

Currently open trials in the same condition.

NCT07412691 — A Study to Evaluate the Safety of BG-A3004 in Healthy Participants and Patients With Immune-Mediated Skin Diseases · Phase 1 · recruiting
NCT07091604 — An Observational Study to Assess Objective Skin Pigmentation Variation. · recruiting
NCT07158879 — Skin Reactions Related to Thoracic Implantable Chamber Dressings · recruiting
NCT06850311 — Herbal Ointment in Treating Atopic Dermatitis Topically · Phase 2, PHASE3 · recruiting
NCT06563323 — Guselkumab in the Treatment of Adults With Pyoderma Gangrenosum (PG) · Phase 2 · recruiting

Other Xiangya Hospital of Central South University trials

Trials by the same sponsor.

NCT07482670 — Efficacy and Safety of Camrelizumab Plus Rivoceranib and Local Therapy for Hepatocellular Carcinoma With Lung Metastases · not yet recruiting
NCT07412223 — Effect of Tegileridine on Postoperative Bowel Function Recovery in Abdominal Surgery · Phase 4 · not yet recruiting
NCT07369960 — Repetitive Transcranial Magnetic Stimulation Combined With Language Training for Language Disorders in Children With Glo · NA · recruiting
NCT07369999 — Effects of Butylphthalide Enhanced With Tenecteplase on Neurological Function in Mild Disabling Acute Ischemic Stroke · Phase 3 · not yet recruiting
NCT07309913 — China Atrial Fibrillation With Complex Metabolic Disorder Cohort Study (CAME Cohort) · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05488860 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Xiangya Hospital of Central South University
Last refreshed: 5 August 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05488860.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing